Background: Benign prostatic hyperplasia (BPH) is a common urological disorder leading to
dysuria in middle-aged and elderly men and significantly reduces the quality of life of …

Introduction This qualitative research study was conducted to develop a novel,
comprehensive, patient-reported outcome measure (PRO), the “Symptoms and Impacts of …

Introduction: Darolutamide is a structurally unique secondgeneration androgen receptor
antagonist that has been approved for indications in patients with non-metastatic castration …

The rapidly expanding treatment options for patients with castration resistant prostate cancer
(mCRCP) are promising. However, there is a need for biomarkers to help clinicians …

For several years, prostate cancer has remained the most common malignancy in male
patients in Poland. A large number of patients combined with rising costs of therapy translate …